Stay updated on Efficacy & Safety of M2951 in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page.

Latest updates to the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.5%
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.4%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check48 days agoChange DetectedThe page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.SummaryDifference0.0%
- Check55 days agoChange DetectedThe web page has been updated to include new data on the administration and assessment of Evobrutinib and Tecfidera in clinical trials, with specific details on dosages, treatment periods, and assessment metrics. Additionally, there are updates to the publication dates and references related to the studies.SummaryDifference33%
Stay in the know with updates to Efficacy & Safety of M2951 in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page.